ACADIA PHARMACEUTICALS INC (ACAD) Form 8-K — Oct 23, 2026

$ACADForm 8-KItems 5.02Filed Oct 23, 2026, 4:51 PM ET0001193125-26-430596Original filing

Acadia Pharmaceuticals' Head of Research and Development, Elizabeth H.Z. Thompson, Ph.D., ceased employment effective October 23, 2026, completing a retirement first announced in the company's May 1, 2026 8-K. Dr. Thompson will remain as a limited consultant through December 31, 2026 to support the transition.

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.